For the first time, leading prostate cancer specialists say they have a drug
that can significantly cut men's risk of developing the disease, dropping the
incidence by 30 percent.
But the discovery, arising from a new analysis of a large federal study, comes
with a debate: Should men take the drug?
Prostate cancer is unlike any other because it is relatively slow-growing, and
while it can kill, it often is not lethal. In fact, most leading specialists
say, a major problem is that men are getting screened, discovering they have
cancers that may or may not be dangerous and opting for treatments that can
leave them impotent or incontinent.
So should healthy men take a drug for the rest of their lives to avoid getting,
and being treated, for a cancer that, in most instances, it would be better to
leave undiscovered and untreated? Is it worth risking a chance that
unanticipated side effects may emerge years later if millions of men with no
prostate problems take the drug?
Some prostate cancer specialists say the answer is yes. Any man worried enough
about prostate cancer to be screened might consider it, they say.
The drug, finasteride, is available as a generic for about $2 a day, and
millions of men safely take it now to shrink their prostates, its approved use.
With finasteride, as many as 100,000 cases of prostate cancer a year could be
prevented, said Dr. Eric Klein, director of the Center for Urologic Oncology at
the Cleveland Clinic.
Dr. Howard Parnes, chief of the prostate cancer group at the National Cancer
Institute's division of cancer prevention, also is convinced. "There is a
tremendous public health benefit for the use of this agent," he said.
While it might seem convoluted to offer a drug to prevent the consequences of
overtreatment, that is the situation in the country today, others say.
Preventing the cancer can prevent treatments that can be debilitating, even if
the cancers were never lethal to start with.
"That's the bind we're in right now," said Dr. Christopher Logothetis, professor
and chairman of genitourinary medical oncology at M.D. Anderson Cancer Center in
Houston. "Most of the time, treatment wouldn't help and may not be necessary.
But the reality is that people are being operated on."
"We are trying to avoid a diagnosis to avoid a prevention whose value is
disputed," he said. With finasteride, Logothetis added, "we're trying to
overcome our other sins."
Other experts say, Not so fast. Finasteride might not make much of a difference
in the death rate, because so few men die from prostate cancer. What the drug's
proponents are advocating is taking a drug to somehow compensate for what many
believe is the nation's overzealous diagnosis and treatment of the disease.
Dr. Peter Albertsen, a prostate cancer specialist at the University of
Connecticut, explains: While 10 percent of men 55 and older find out they have
prostate cancer, the cancer is lethal in no more than 25 percent of them. So if
finasteride reduced prostate cancer's incidence by 30 percent, about 7 percent
of men would get a cancer diagnosis and approximately 1.8 percent instead of 2.5
percent would have a lethal cancer.
"Finasteride might make a difference, but only in a very small subset of men,"
Albertsen said.
And, he adds, the study did not look for a decline in death rates, and it is
unlikely that any study ever will - it would take too long and be too expensive.
Yet the ultimate goal of prevention is to save lives. It remains an assumption
that finasteride would have much effect on the minority of prostate cancers
that, despite early detection and treatment, still kill.
Finasteride blocks the conversion of testosterone to dihydrotestosterone, a
hormone active mostly in the prostate and the scalp and that all prostate
cancers need to grow. The drug is available from Merck, as Proscar, and from six
companies as a generic to shrink the prostate in older men, whose prostates can
enlarge, making urination difficult.
Researchers say it turns out that shrinking the prostate also may be good for
cancer detection by making it easier to find all tumors, including the most
aggressive.
"The data are compelling," said Dr. Peter Scardino, chairman of the department
of surgery at Memorial Sloan-Kettering Cancer Center in New York, a convert who
originally thought the drug was dangerous. "Finasteride has to be recognized as
the first clearly demonstrated way to prevent prostate cancer with any
medication or any oral agent at all."
Finasteride has had its ups and downs. Its chronicle began in 1993, with the
start of a study sponsored by the National Cancer Institute and involving 19,000
men. Half took finasteride pills; the rest a placebo. In March 2003, 15 months
before the study's scheduled end, its directors halted it abruptly. The reason
was that the results were overwhelmingly compelling - men taking the drug were
not getting prostate cancer. Yet despite that note of triumph, a troubling
finding emerged. The study was designed to look for a reduction in the overall
prostate cancer rate. And that is what it found. But, as Scardino pointed out in
an editorial five years ago in The New England Journal of Medicine that
accompanied the study, it appeared that 6.4 percent of the men who took the drug
got fast-growing, ominous-looking tumors. In contrast, such tumors were found in
5.1 percent of men who took the placebo. The concern was that the drug might be
preventing cancers that never spread. At the same time, finasteride might
actually be causing aggressive cancers that can kill. It would, of course, be
the worst possible outcome. Scardino's editorial warned healthy men not to take
finasteride. That seemed to leave the drug dead. The study researchers, though,
wondered if that conclusion was correct. Maybe, they thought, by shrinking the
prostate, the drug was just making it easier to find aggressive tumors. When
doctors do a biopsy for prostate cancer, they probe the gland with a needle,
hoping to find cancer cells. But prostate cancer grows as little nests, and an
aggressive cancer will appear as dangerous-looking cells in some clusters and
less dangerous in others.A smaller prostate means a doctor is more likely to hit
upon cancer nests and more likely to find aggressive-looking cells. The
researchers had a way to learn if they were correct. Most of the men in the
study who had cancer - aggressive or not - chose to be treated and many had
their prostates removed. A pathologist could carefully examine every one of
those 500 prostates and compare the kinds of cancers found at surgery to those
initially diagnosed at biopsy. It took years, but the analysis showed the
hypothesis was right.Now, two groups of independent researchers conclude, in
papers in the current issue of Cancer Prevention Research, that finasteride
decreases the risk of having any tumor at all - large or small, fast-growing or
slow-growing, by the same amount - nearly 30 percent. With this new analysis,
many prostate cancer specialists, including Scardino, say their view of the drug
has completely changed. The study actually found that finasteride protects
against both lethal and less-dangerous tumors and could cut prostate cancer risk
by nearly a third. Even the effect on smaller tumors has important implications,
said Dr. Ian Thompson Jr., the study's principal researcher and a urologist at
the University of Texas Health Science Center in San Antonio. "The cancers that
were prevented were the ones men are having surgery and radiation for today,"
Thompson said. Now, though, prostate cancer specialists have a new problem: How
can they change the drug's image? Drug companies are unlikely to be
instrumental, Thompson and others say, because finasteride's patent has expired,
giving companies little incentive to apply to the Food and Drug Administration
to market it as a cancer preventative. Without FDA approval, finasteride cannot
be advertised as preventing cancer, and insurers may not pay for it. But doctors
can prescribe drugs for other purposes at their discretion, and Parnes said that
men and their doctors may be persuaded to try it. In the meantime,
GlaxoSmithKline, which has a patented drug, Avodart, to reduce the size of men's
prostates, has a study asking whether its drug can prevent prostate cancer. If
it can, and the drug agency approves Avodart for cancer prevention, doctors and
patients may have to decide between a generic drug used off-label or a more
expensive brand-name drug that does much the same thing. Some leading prostate
specialists, like Scardino, say they are recommending that men who worry about
prostate cancer take finasteride. He also ponders taking it himself. "I
regularly think, 'Why don't I take it? Why wouldn't every man take it?"'
Scardino said. He hasn't done so yet, partly because those years of concern
about the drug took a toll. "I think it's the difficulty of adjusting to
something that originally had a bad reputation," Scardino explained. Thompson
has no such fears. He is at no particular risk for prostate cancer, but, he
reasons, taking finasteride is not that different from taking a statin for a
slightly elevated cholesterol level. "Imagine the marathoner with no family
history of heart disease, who's skinny, doesn't smoke and has normal blood
pressure," Thompson said. "Should he take a statin? The amount of benefit he'll
get is not much, but his risk reduction still is 25 or 30 percent." Thompson
knows what he will do about finasteride. "I'm 54," he said. "The men in the
study were 55 and older. So I'll start taking it next year."
Source : The New York Times
